AVROBIO reports Q4 net loss $25.0M, full-year 2022 loss $105.9M; cash $92.6M

Tectonic Therapeutic, Inc.

Net loss of $25.0M in Q4 2022 vs $28.2M in Q4 2021; full year loss $105.9M vs $119.1M.
R&D expenses $18.1M (Q4) and $72.2M (FY); G&A expenses $7.1M (Q4) and $33.2M (FY).
Cash and equivalents $92.6M as of Dec 31, 2022, down from $189.6M a year earlier; expects to fund operations into Q1 2024.
Plan to initiate registrational global Phase 2/3 trial (Guard3) for Gaucher disease type 3 in H2 2023, subject to regulatory alignment.
Collaborator-sponsored Phase 1/2 trial for cystinosis completed dosing; late-stage activities planned H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tectonic Therapeutic, Inc. reported financial results for the three months and year ended December 31, 2022.

Period: the three months and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 23, 2023, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three months and year ended December 31, 2022.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Tectonic Therapeutic, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-013237

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.